OTC Continuous Glucose Monitoring Market Size & Share 2025 – 2034

OTC Continuous Glucose Monitoring Market Size

The global OTC continuous glucose monitoring market was valued at USD 370.7 million in 2024 and is projected to exhibit 16.9% CAGR from 2025-2034. OTC CGM includes Continuous Glucose Monitoring system which is available for purchase and use without a prescription from a healthcare professional. While continued glucose monitoring (CGM) devices are prevalent in diabetes management, the application of OTC continuous glucose monitoring for monitoring preventive health goes beyond the diabetes population.

According to a Morning Consult survey, in January 2023, 35% of adults in the U.S. reported using a wearable healthcare device, a growth of 8 percentage points from April 2018. The adoption of consumer health monitoring devices, particularly CGM's, highlights a market responding to the growing demand for personal health information for proactive decision making around health management.
 

Over-the-counter continuous glucose monitors (OTC CGM's) are moving closer to becoming mainstay components in preventive health approaches and personalized nutrition approaches to health management. This new class of OTC CGM's enable users to get real-time feedback of how food intake and physical exercise impacts their glucose levels to support proactive health management and engagement for wellness and fitness.
 

The advancement of more precise sensors, small form factors, longer wear times, and smart device integration have increased the market for OTC CGM's by appealing more broadly to the general population. The FDA also reported in their November 2021 “Special Features” that modern CGM sensor devices are achieving a mean absolute relative difference (MARD) of less than 10% and are extending wear times to 14 days. Together these advances are indicating considerable improvements in regard to the reliability and usability of the OTC CGM devices.
 

CGM Manufacturers and fintech, or digital platforms for consumers, are partnering to provide, as an example, analytics and artificial intelligence data, or lifestyle coaching to improve product adoption and functionality for consumers interested in monitoring health and wellness. To highlight this innovation, in May 2023, Dexcom announced a partnership with Oura which marked the official integration of 2 services, from a user that adopts both systems.
 

OTC Continuous Glucose Monitoring Market Trends

• Outside of traditional diabetic management, OTC CGMs are increasingly appealing to a wide range of user groups, such as fitness or health enthusiasts, biohackers, longevity seekers, or anyone wanting to manage stress or hormonal health, thereby expanding the applications of OTC CGM devices.
   
• These users are using CGM data to understand how their dietary choices, exercise regimen, and lifestyle choices impact their metabolic health. Health optimization is the fastest growing demand in the consumer health space and also a significant driver of market growth.
   
• Innovation is spurring the development of non-invasive or minimally invasive CGM devices that lessen or eliminate skin punctures. These technologies improve the user experience to help overcome barriers associated with traditional CGMs and broaden the potential appeal and uptake of glucose monitoring.
   
• Technologies like optical sensors and transdermal monitoring resonate with consumers who are primarily wellness-oriented and want to track their health regularly with as little discomfort as possible.
   
• Further, artificial intelligence (AI) is rapidly becoming an integral feature of OTC CGM platforms, creating predictive analytics and bespoke health insights. AI algorithms assess the continuous flow of glucose data to pinpoint trends and predict glucose spikes, then can alert users to potential hyperglycemic or hypoglycemic events. With recommendations delivered via AI, users can make informed decisions about their food intake and exercise that can lead to improved health outcomes.
   
• In order to provide a complete overview of a user’s health, platform as a service providers like Nutrisense are incorporating their platforms with smart wearable technologies like Apple Watch, Fitbit, and Garmin. This allows users to correlate glucose data with other health indicators including physical activity and sleep patterns.
   

OTC Continuous Glucose Monitoring Market Analysis

Based on component, the market is segmented into sensors and platforms/apps. The sensors segment dominates the market and was valued at USD 329 million in 2024.
 

• The increasing demand for compact, user-friendly wearables has affected the design of sensors that comprise over-the-counter (OTC) continuous glucose monitors (CGMs). Growing demand from end users for the devices that are smaller, lightly worn, comfortable, and adapt to the skin more harmoniously, is driving innovations in sensor technologies.
   
• The wearable medical devices/sensors that are being developed by vendors are increasingly using innovative materials, including graphene, stretchable electronics, and flexible polymers, all of which make the user experience more comfortable and increase the accuracy of measurement.  For instance, Dexcom Stelo and Abbott Libre Rio have smaller sensor size and are light weight.
   
• The latest advancements in sensors have also enabled their integration with smartphones, wearables, and AI platforms. This integration has fostered advanced communication technologies, real-time connectivity, minimal power usage, and robust data transfer. Development of digital health systems and wellness monitoring programs is further propelling innovation in personalized health devices, and sensors that provide remote cloud analytics, thereby improving accuracy through seamless accuracy integration with external monitoring systems. Such advancements in sensor technologies and designs are driving their adoption, further contributing to market growth.
   
• In addition, many platform providers are offering third party sensors from key manufacturers such as Dexcom and Abbott. In countries such as the U.S., these devices are being made available through off-label prescriptions to non-diabetic users. Such initiatives are contributing to increasing revenue growth in the sensors segment.
   

Based on consumer type, the OTC continuous glucose monitoring market is segmented into non-diabetic health enthusiasts, pre-diabetic and at-risk individuals, and other consumer types. The pre-diabetic and at-risk individuals segment dominated the market with the largest revenue of USD 167.1 million in 2024.
 

• The healthcare paradigm is globally shifting away from a reactive disease treatment approach to proactively managing health, particularly in the context of chronic illness, such as diabetes. Over-the-counter continuous glucose monitors (OTC CGMs) support this paradigm shift as they provide at-risk individuals real-time feedback on how their lifestyle factors, including diet, physical activity, and stress, impact their glucose levels.
   
• This feedback encourages healthier behaviors, assists in mitigating long-term healthcare costs, and allows individuals to take more control of their chronic disease management or prevention.
   
• The American Diabetes Association reports the global prevalence of impaired glucose tolerance (IGT) was 9.1%, or approximately 464 million people in 2021.  Given a previous global prevalence of unhealthy glucose levels of around 1%, this rise in at-risk individuals brings urgency for accessible tools to support early intervention.
   
• Over-the-counter (OTC) continuous glucose monitors (CGM) can support immediate and real-time glucose monitoring and empower individuals to respond to and identify their own metabolic imbalances, preventing further escalations in state of health and progression to type 2 diabetes. Such factors are contributing to the revenue growth in the pre-diabetic and at-risk individuals segment.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channel, the OTC continuous glucose monitoring market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The e-commerce segment dominated the market with a share of 56% in 2024.
 

• The availability of over-the-counter continuous glucose monitors  (OTC CGMs) through e-commerce platforms can be attributed to some key factors that reflect a larger shift in consumer behavior and uptake of health technology.
   
• Health-conscious consumers are opting out of retail and clinical settings when considering the purchase of wellness products, taking the online approach. E-commerce platforms allow consumers direct access to OTC CGMs as they express growing autonomy in their digital health.
   
• Key OTC CGM sensor manufacturers and platform providers are offering their services through direct-to-consumer model. This model focuses on using direct online ordering through digital stores/website. The direct-to-consumer model supports user privacy and device convenience, plus allows brands to educate and communicate with users without relying on an in-store experience. As a result, increasing number of end users are procuring OTC CGM through e-commerce.
   
• Further, e-commerce platforms support consumers without access to brick and mortar pharmacy locations. End users can order OTC CGMs across remote locations, usually either through a subscription to recurring shipment or trial package options.
   
• Further, e-commerce platforms typically provide more access to device models and bundles than the retail store experience, supporting users to personalize their monitoring approaches to fit their needs and goals, which further drives the revenue growth in the segment.
   

The North America OTC continuous glucose monitoring market was valued at USD 159.2 million in 2024 and is expected to grow at a CAGR of 17.1% over the forecast period. The market is driven by the availability of advanced OTC CGM in the U.S.
 

The U.S. market is projected to grow significantly from USD 144.8 million in 2024 to USD 1.1 billion by 2034.
 

• The emerging trend of preventive health and personal wellness in the U.S. is leading consumers, especially non-diabetics, to monitor glucose to optimize diet, exercise and overall metabolic performance. It contributes to an increase in demand for over-the-counter continuous glucose monitors (CGMs) as a lifestyle tool and not just as a medical device.
   
• The FDA's progressive direction in regard to CGMs and easing access to CGMs, as well as recent approvals for OTC use (for example Dexcom Stelo) demonstrate a regulatory tailwind. These simple approval mechanisms has minimized barriers to entry for manufacturers, while at the same time creating consumer confidence and ultimately increased use of self-managed glucose monitoring.
   
• The widespread use of smartphones and expectations for personalized health insights are compelling the development of CGMs to be easily integrated with health applications and wearable ecosystems.
   
• In the U.S. the adoption of digital health is considerably high. Availability of OTC CGM devices for non-prescription users through convenience is substantially increasing the adoption of CGMs among health-focused early adopters that are also early tech adopters for lifestyle devices, which is contributing to market growth.
   

Europe OTC continuous glucose monitoring market was valued at USD 107.2 million in 2024 and is expected to grow at a CAGR of 16.6% over the forecast period.
 

• Europe's escalating challenges with diabetes (and prediabetes), driven by an aging population and lifestyle changes, is creating demand for affordable metabolic monitoring tools. Diabetes UK reported, as of February 2025, approximately 6.3 million people in the UK are living with prediabetes. Over-the-counter continuous glucose monitoring (OTC CGM) devices present a method, non-invasive and hassle-free to identify glucose sooner than relying on a continual clinical burden of engagement with the patient. OTC CGM's offer patients a way to monitor glucose and respond to metabolic health without the continuous reliance on clinical visits.
   
• In addition, growing interest towards preventive health practices and proactive chronic disease management, together with availability of well-developed public health infrastructure throughout Europe is also supporting market growth. The OTC CGM devices seamlessly fit into national healthcare strategies in the region, that focuses on early intervention to relieve chronic disease and system costs.
   
• Simultaneously, consumer interest in personalized health and wellness is driving a growing focus towards real-time health monitoring. Health conscious consumers are becoming more responsive to personalized metabolic health and are increasingly purchasing OTC CGMs to enhance their dietary habits, modify their exercise programs, assess metabolic health associated with stress levels.
   
• In European countries such as UK, with the NHS facing demands from staffing shortages and budgets, UK health policy is increasingly pushing patients to self-manage chronic health disorders and at-risk conditions. OTC CGMs help support this paradigm shift as they allow scope for self-monitoring and self-act of glucose data without frequent reliance on clinical appointments.
   
• Public awareness in the UK about pre-diabetes, insulin resistance and metabolic syndrome is shifting attention forward, and with reclaimed interest by health bodies and NGOs and an increase of obesity incidence in the UK, end users are now interested in using tools such as OTC CGMs, to experience early interventions and track the metabolic process.
   
• End users in UK are also focusing more to personalized nutrition planning, as an approach to health, driven by the convergence of apps, wearable technologies and evidenced benefits from gut health. According to the Elsevier Journal, about 5% of population in UK were affected with irritable bowel syndrome. OTC CGM is enabling end users to use real time information to make the best informed decisions about individual diet selections, based on glycaemic responses unique to them.
   

The Asia Pacific OTC continuous glucose monitoring market is expected to grow at the fastest CAGR of 6.7% over the forecast period.
 

• The Asia Pacific region has seen an unprecedented increase in the prevalence of prediabetes largely facilitated by urbanization and changing diets promoting sedentary lifestyles among genetically predisposed South and East Asian populations.
   
• Disease burdens from chronic metabolic disorders are already beginning to overwhelm healthcare systems, resulting in the end-user emergence of over-the-counter continuous glucose monitoring (CGM) devices as attractive non-invasive and accessible means of early detection and real-time glucose monitoring. Now, individuals can use CGMs as appropriate devices of early prevention or self-awareness prior to treatment, thus alleviating some of the burden on public healthcare systems.
   
• Furthermore, a heightened awareness of lifestyle-related diseases and metabolic health has also contributed to rising demand for personal health tracking tools in the Asia Pacific region. Consumers in urban centres are increasingly demonstrating more proactive behaviours regarding the management of their wellness goals such as weight management, insulin sensitivity improvement, and stress management behaviours.
   
• Over-the-counter CGMs are emerging as an epistemic device for individuals to engage in real-time and personal health awareness about how their bodies respond to food consumption, physical activity, and stress. Increasing health literacy, and the willingness to utilize biofeedback is resulting in new demands for CGMs for non-traditional diabetes care.
   

Rest of the World OTC continuous glucose monitoring market is anticipated to witness lucrative growth between 2025 – 2034.
 

• In Latin America region, countries such as Brazil have one of the highest rates of Type 2 diabetes and obesity in Latin America, and millions of individuals are either undiagnosed or pre-diabetic. This growing public health burden is raising interest in over the counter (OTC) continuous glucose monitors (CGMs) as a tool for early detection, lifestyle monitoring, and preventative care, especially among younger individuals.
   
• Majority of Brazil's population, particularly in rural and interior region, has limited access to endocrinologists and diabetes specialists. OTC CGM devices are offering a decentralized, patient-controlled means of tracking glucose without needing to visit a clinical facility, which poses an advantage in rural areas.
   
• In the Middle East and Africa region, obesity and type 2 diabetes rates are among the worst in the world, specifically in countries such as Saudi Arabia, due to sedentary lifestyles and diet. As such, glucose monitoring becomes important, and OTC CGMs are on the market with an accessible option that is non-invasive and allows a pre-diabetic and at-risk individuals to manage their health proactively without a prescription or frequent visits to a clinics in Saudi Arabia.
   

OTC Continuous Glucose Monitoring Market Share

The OTC continuous glucose monitoring industry has a dynamic mix of international and domestic players providing biosensors and platforms. Companies such as Abbott Laboratories and Dexcom are some of the dominant competitors in the market accounting for a combined market share of approximately 89%.
 

Established companies in the OTC continuous glucose monitoring (CGM) market including Abbott Laboratories, Dexcom, Nutrisense, Zoe, and Levels are actively implementing strategic initiatives to enhance their global presence and competitiveness. These strategies encompass product innovation, strategic partnerships, regulatory approvals, and market expansion, all aimed at addressing unmet medical needs and strengthening their positions in the evolving OTC CGM sector. For example, Abbott Laboratories has made significant strides in the OTC CGM market with the FDA clearance of two new devices: Lingo and Libre Rio. These systems are based on Abbott's FreeStyle Libre technology. Lingo is designed for health-conscious individuals seeking to monitor their glucose levels. In addition to product innovation, Abbott is focusing on expanding its market reach. The company has announced plans for a comprehensive marketing campaign for Lingo, including television advertisements and grassroots marketing efforts, to effectively reach consumers beyond the traditional diabetes market.
 

OTC Continuous Glucose Monitoring Market Companies

Some of the eminent market participants operating in the OTC continuous glucose monitoring industry include:

• Abbott Laboratories
• Dexcom
• January AI
• Levels Health
• Limbo (Vitals in View)
• Nutrisense
• Sinocare
• Ultrahuman Healthcare
• Veri
• Zoe
   
• Dexcom's unique selling proposition (USP) in the OTC CGM market is its clinical-grade accuracy and trusted consumer-appropriate design. Dexcom also became the first player in the U.S. to launch a fully FDA-cleared OTC CGM product (Dexcom Stelo), which was designed specifically to work with those who do not use insulin (prediabetic consumers). Stelo was conceived and engineered for simplicity, comfort, and discretion, using no finger sticks or calibrations.
   
• Abbott Laboratories through its free style brand transformed the glucose tracking industry specifically after the launch of free style libre solutions. In 2024, Abbott became the first company to receive FDA clearance for two over-the-counter CGM devices, Libre Rio for people with type 2 diabetes and Lingo for general wellness enabling broader public access without the need for a prescription. Its technology integrates continuous sensor data with intuitive mobile apps to deliver personalized feedback and support behavioral changes.
   
• Levels Health is different than Dexcom in that it layers a powerful behavioral science platform over top of CGM hardware—in fact, it gets its CGM from clinical partners like Dexcom. While Levels Health may eventually build its own CGM device, its USP is not the CGM device itself, but rather the personalized metabolic insights it produces using its app, to help users comprehend how consuming specific foods, engaging in exercise, and having stress impacted their glucose levels.
   

Wearable Bioelectronic Skin Industry News

• In September 2024, Abbott introduced its latest wearable, Lingo, a continuous glucose monitor, aimed at health-conscious individuals by helping them track their glucose levels without needing prior medical approval. This launch expanded the company’s product portfolio of continuous glucose monitors and may enable them to increase customer base.
   
• In June 2024, Abbott announced U.S. Food and Drug Administration (FDA) clearance for its two new over-the-counter continuous glucose monitoring (CGM) systems, Lingo and Libre Rio, based on FreeStyle Libre continuous glucose monitoring technology. This approval increased the company’s competitiveness in the market.
   
• In March 2024, Dexcom received FDA clearance for its Stelo glucose biosensor, marking it as the first over-the-counter (OTC) continuous glucose monitor (CGM) available in the U.S. This move is expected to position Dexcom as a leading player in the OTC CGM market, responding to increasing demand for accessible glucose monitoring tool among non-diabetic population.
   

The OTC continuous glucose monitoring market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Component

• Sensors
• Platforms/Apps

By Consumer Type

• Non-diabetic health enthusiasts
• Pre-diabetic and at-risk individuals
• Other consumer types

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Rest of the World